TROPION-Lung01 Study Design and Baseline demographics

TRAES Occurring in ≥10% of Patients Dato-DXd N=297 Docetaxel N=290 System organ class Preferred term, n (%) Blood and lymphatic system Any grade Grade ≥3 Any grade Grade ≥3 Anemia Neutropeniaª Gastrointestinal Stomatitis 43 (15) 11(4) 59 (20) 12(4) 2(1) 76 (26) 11(4) 68 (23) 140 (47) 19(6) 45 (16) 3(1) Nausea 100 (34) 7(2) 48 (17) 3(1) Vomiting 38 (13) 3 (1) 22(8) 1 (0.3) Constipation 29 (10) 0 30 (10) 0 Diarrhea 28 (9) 1 (0.3) 55 (19) 4(1) General Asthenia 55 (19) 8 (3) 55 (19) 5(2) Fatigue 34 (11) 2(1) 40 (14) 6(2) Metabolism and nutrition Decreased appetite 68 (23) 1 (0.3) 45 (16) 1 (0.3) Skin and subcutaneous Alopecia 95 (32) 0 101 (35) 1 (0.3)b Rash 36 (12) 0 18 (6) 0 Pruritus 30 (10) 0 12(4) 0 TRAE, treatment-related adverse event. *This category includes the preferred terms "neutropenia" and "neutrophil count decreased". "Includes an event incorrectly reported as grade 3. • Stomatitis and nausea were the most Daiichi-Sankyo frequent TRAEs seen with Dato-DXd and were predominantly grade 1 or 2 Hematologic toxicities, including neutropenia and febrile neutropenia, were more common with docetaxel • No new safety signals were observed with Dato-DXd 14

View entire presentation